Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Third Consecutive Year
Acorda Therapeutics, Inc. (Nasdaq: ACOR)
today announced that the Company has been named as one of the Best
Companies to Work for in New York for the third consecutive year, based
on an independent survey by the Best Companies Group (BCG) identifying
the best employers in the state. Acorda was ranked 2nd among
large companies, defined as employing more than 250 people. The rankings
are determined by feedback from employees about company culture,
benefits and overall job satisfaction.
“We are honored that Acorda has been named one of the best places to
work in New York for the third consecutive year. Every day, our team of
more than 350 associates works to develop cutting edge medicines that
can improve the lives of people living with nervous system diseases. To
do so successfully relies heavily on attracting and retaining the most
talented and collaborative people in the industry,” said Ron Cohen,
M.D., Acorda’s President and CEO. “We continually work to provide an
environment that incorporates a sense of fun, while fostering teamwork,
integrity and professional growth. The Best Places to Work recognition
highlights that Acorda has maintained a strong corporate culture that
values the contributions of all of our associates, even as we’ve grown
significantly over the past few years.”
Acorda was among only 20 large companies statewide to be recognized for
this achievement.
The Best Places to Work survey was conducted by BCG, an independent
company that manages Best Places to Work programs on state, regional and
national levels. The survey was a partnership between the New York State
Society for Human Resource Management, the Business Council of New York
and BCG.
About Acorda
Therapeutics
Acorda Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with MS,
spinal cord injury and other neurological conditions.
Acorda markets AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, in the United
States as a treatment to improve walking in patients with multiple
sclerosis (MS). This was demonstrated by an improvement in walking
speed. AMPYRA is marketed outside the United States as FAMPYRA®
(prolonged-release fampridine tablets) by Biogen Idec under a licensing
agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license
from Alkermes Pharma Ireland Limited.
The Company also markets ZANAFLEX
CAPSULES® (tizanidine hydrochloride) and Zanaflex
tablets, a short-acting drug for the management of spasticity. Acorda
also receives sales royalties on tizanidine hydrochloride capsules, an
authorized generic version of ZANAFLEX CAPSULES, distributed by Actavis,
Inc. under its agreement with Acorda.
Acorda has one of the leading pipelines in the industry of novel
neurological therapies. The Company is developing Diazepam Nasal Spray
for treatment of certain epileptic seizures. It is also studying AMPYRA
to improve a range of functional impairments caused by MS, as well as
its potential for use in other neurological conditions, including
cerebral palsy and post-stroke deficits. In addition, Acorda is
developing clinical stage compounds AC105 for acute treatment of spinal
cord injury, GGF2 for treatment of heart failure and rHIgM22, a
remyelinating monoclonal antibody, for the treatment of MS. GGF2 is also
being investigated in preclinical studies as a treatment for
neurological conditions such as stroke and peripheral nerve damage.
Chondroitinase, an enzyme that encourages nerve plasticity in spinal
cord injury, is in preclinical development.
Acorda Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including our ability to successfully market and sell Ampyra in the
U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including Diazepam Nasal Spray or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully market
Diazepam Nasal Spray or other products under development; the occurrence
of adverse safety events with our products; delays in obtaining or
failure to obtain regulatory approval of or to successfully market
Fampyra outside of the U.S. and our dependence on our collaboration
partner Biogen Idec in connection therewith; competition, including the
impact of generic competition on Zanaflex Capsules revenues; failure to
protect our intellectual property, to defend against the intellectual
property claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; failure to
comply with regulatory requirements could result in adverse action by
regulatory agencies; and the ability to obtain additional financing to
support our operations. These and other risks are described in greater
detail in Acorda Therapeutics' filings with the Securities & Exchange
Commission. Acorda may not actually achieve the goals or plans described
in its forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in this
release are made only as of the date hereof, and Acorda disclaims any
intent or obligation to update any forward-looking statements as a
result of developments occurring after the date of this release.
